Baxter and Halozyme release HyQ results; Stimulating antibiotic R&D;

@FierceBiotech: Innate shares soar on record $465M antibody pact with BMS. News | Follow @FierceBiotech

@JohnCFierce: I'm still wondering if developers have turned a corner, or if this is just a lucky streak. How would you vote? | Follow @JohnCFierce

> Baxter and Halozyme released positive Phase III results for HyQ, a facilitated subcutaneous immune globulin product for primary immunodeficiency patients. The 89 patient trial good safety and tolerability, with the most reported side effects being infusion site reactions, headaches, fatigue and pyrexia. Release

> Adding a total of $4 million to its venture capital round, SpringLeaf Therapeutics has now raised $19 million in Series B financing. As part of the deal, SpringLeaf will welcome Enrico Petrillo, managing director of Excel Venture Management to its board of directors as an observer. Item

> The Office of Health Economics has called for new incentives for antibiotics in order to entice companies to focus on the growing superbug threat. The report suggests upfront registration payments rather than volume of use payments or accelerated review processes for antibiotics to stimulate growth in antibiotic R&D. Story

> SymBio has secured the rights to develop Onconova Therapeutics' cancer therapy rigosertib in Japan and Korea. Onconova will receive an upfront payment, development milestones and sales royalties. Article

> InterMune has started a Phase III trial, ASCEND, using pirfenidone to treat idiopathic pulmonary fibrosis patients. Patients in the one-year, double-blind study will receive 2403 mg of pirfenidone per day, or a placebo. InterMune release

Pharma News

@FiercePharma: Bayer joins social media follies with tweet apology. Piece | Follow @FiercePharma

> Pfizer move disappoints break-up champions. Story

> Sanofi's Multaq takes hit from trial failure. News

> PDUFA committee hearing draws a crowd. Report

> Lilly chief scolds Germany for new pharma rules. Article

And Finally... The first synthetic windpipe transplant has been completed. The windpipe was grown from stem cells from the patient's hip, and unlike donated organs, should not have the risk of being rejected. Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.